Chuo Li

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL.

S. Zuo, Q. Zheng, Xiaoming Feng, 2019, Blood.

A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL

Wei Cheng, Jianfeng Zhou, H. Cai, 2021, Blood Cancer Journal.

Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia

Dongming Zhou, S. Zuo, Huifang Huang, 2021, Journal of Hematology & Oncology.

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL

Xiaoming Feng, B. Deng, Jing Pan, 2021, Frontiers in Oncology.

Myeloid leukemia-derived galectin-1 downregulates CAR expression to hinder cytotoxicity of CAR T cells

Xiaoming Feng, Chuo Li, Huifang Huang, 2024, Journal of translational medicine.